Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Cerity Partners LLC

Cerity Partners LLC trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,386 shares of the medical equipment provider’s stock after selling 1,511 shares during the quarter. Cerity Partners LLC’s holdings in Lantheus were worth $929,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new position in shares of Lantheus in the 4th quarter worth approximately $36,183,000. Swedbank AB lifted its stake in Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Keybank National Association OH acquired a new stake in shares of Lantheus in the fourth quarter valued at $27,526,000. Norges Bank acquired a new stake in shares of Lantheus in the fourth quarter valued at $26,189,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Lantheus in the 4th quarter valued at $20,022,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Performance

LNTH opened at $101.32 on Friday. The business’s 50-day simple moving average is $95.39 and its 200-day simple moving average is $95.45. The company has a market cap of $6.94 billion, a P/E ratio of 16.86 and a beta of 0.20. Lantheus Holdings, Inc. has a one year low of $62.59 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Truist Financial boosted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Finally, JMP Securities restated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and an average price target of $129.43.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock valued at $6,016,046 in the last three months. 1.50% of the stock is currently owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.